Eroom's law (Moore's law spelled backwards), describes adverse trends towards declining innovation and rising costs of drug development over the last several decades. Therapeutics for cardiovascular diseases (CVD) appear to have been particularly sensitive to these trends. Thirty-three percent fewer CVD therapeutics were approved between 2000 and 2009 compared to the previous decade, and the number of CVD drugs starting all clinical trial stages declined in both absolute and relative numbers between 1990 and 2012. In the last 5 years, drugs to treat CVD disease comprised just 6% of all new drug launches. This review discusses the decline in CVD therapeutics, the reasons behind it, and ways in which this trend is being or might be addressed. The author attests he is in compliance with human studies committees and animal welfare regulations of the authors' institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the JACC:
Cardiovascular disease (CVD) accounts for nearly 1 in 3 deaths globally, or over 17 million deaths annually (4, 5) . That number is expected to reach over 24 million by 2030 as developing countries conquer diseases that impede longevity, and shift their focus toward CVD and other chronic diseases affecting their aging populations (6, 7) . Despite this, few drugs that truly improve patient outcomes over existing therapies are reaching clinicians and patients, to meet the anticipated growth in CVD (8) . Medical innovation faces increasing challenges, including formulation of new ideas, R&D barriers, regulatory uncertainty, growing payer pressures and skyrocketing costs of bringing a therapy to market (9, 10) . This review Industry has responded to the challenges of drug development by refocusing on therapeutic areas that optimize probability of market success, reduce development costs, are more likely to reach rapid regulatory approval and are relatively resistant to pricing pressure (9) , thus improving their return on investment (ROI). Those adjustments are negatively impacting CVD therapeutics out of proportion to other clinical areas. Pfizer has 94 clinical product pathways, over one-half of which are devoted to oncology and rare diseases, and only 7 for CVD products (12) . Merck has 17 oncology programs versus 2 CVD programs, and Allergan has no CVD programs (12) . Based on FDA new drug applications, a "tipping point" in therapeutics 
funding, R&D pipeline volumes, and the number of new drug launches that would be needed to generate enough medications to meet this burden. Declining basic science research for CVD therapeutics today will be felt for years to come, because the average timeline for bench-to-market drug development is 12 years (18) .
NEGATIVE IMPACT OF TARGET-BASED RESEARCH.
In 1990, James D. Watson, director of the National Center for Human Genomic Research, predicted that the ability to cost-effectively sequence DNA would "provide the technological bases for a new era in drug development" (19) . RISK ACCEPTANCE AND THRESHOLD. Ultimately, drug approvals occur within an acknowledged benefit/risk balance, and the acceptable threshold for this balance above which a drug license is approved and below which it is denied cannot usually be described by a single metric-and varies highly from drug to drug. Regulators and the public are both more willing to accept a higher level of benefit/risk uncertainty for life-threatening or severe conditions with an unmet medical need compared to less severe conditions. For example, the FDA approved bedaquiline, for drug-resistant tuberculosis (TB) on the basis of only 2 studies involving a total of about 200
patients. Studies showed that bedaquiline improved clearance of TB from patient sputum, but they also Van Norman
demonstrated that patients receiving the drug were about 2.5 times more likely to die of TB than controls (25) . 0% for fast track (vs. 30% and 20%, respectively) and 
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Beyond EROOM's Law 
DOLLARS PER DEATH (HUNDREDS)
*Charities surveyed: Jump Rope for Heart, Koman Race for the Cure, and ALS Ice Bucket
Challenge (45) .
Beyond EROOM's Law estimate that the time to filing for drug approval could be accelerated by 2 to 3 years over current, standard clinical studies, and save almost $42 million over current development costs (34) .
INCENTIVIZING THE COMMERCIALIZATION OF THERAPIES FOR CVD
Several FDA drug approval processes have been created to shorten time from drug conception to market approval for therapies that meet certain requirements, and these all warrant renewed scrutiny with regard to their relevance to CVD therapeutics.
These include fast track, breakthrough therapy and priority review designations, and the FDA accelerated review pathway (Table 1 and 7-year market exclusivity after development independent of the drug's current patent status. Van Norman FAST TRACK DESIGNATION. Fast track designation is for drugs that treat serious illnesses plus fill an unmet medical need. The definition of a "serious illness" is subjective, but generally based on whether the drug will impact disease survival or day-to-day functioning, and the likelihood that if the disease is untreated it will progress to a more serious condition.
Heart failure is 1 example of a disease that carries the Priority review designation is for drugs that treat a serious condition plus provide a significant improvement in efficacy or safety over previous treatments (16) . Priority review designation requires the FDA to take action earlier (6 months vs. 10 months standard review time) on the new drug marketing application.
Beyond EROOM's Law
There are concerns about whether priority review is "safe"-not because it affects requirements for drug efficacy and safety studies (it does not), but because the obligation for shorter review times for new drug applications at the FDA may increase errors in the FDA review process itself. At least 1 study supports this concern: drugs that were approved by the FDA within 2 months of their deadline (i.e., presumably under pressure) were significantly more likely to be withdrawn later or require black box warnings for safety problems (65) . Similar problems have been shown with the other accelerated pathways (66) .
Priority reviews also indirectly increase insurer costs.
If a drug is approved 4 months earlier in its patent, insurers will be required to pay for 4 months of drug with exclusive marketing status and thus higher pricing. Such increases are likely to be passed on to patients in the form of higher insurance premiums.
PRICING POLICIES AND PAYER REIMBURSEMENTS
Pricing practices and payer reimbursement policies significantly affect both the willingness of commercial developers to pursue drug development and the quality of their innovations. An in-depth discussion of pricing, reimbursements, and innovation is beyond the scope of this review, but because pricing in turn affects all drug development, including CVD drugs, it warrants at least a short discussion.
For drug development, "cost-effectiveness" refers to the question of whether a drug is "good value for the money" and whether its effectiveness warrants both the cost of development and the price. In 
MOVING BEYOND EROOM's LAW
Moore's law held for more than half a century, but ultimately become outdated because the very technology for which it was coined approached its limits.
On the other hand, the validity of Eroom's law appears to be going strong, and to be particularly germane with regard to CVD therapeutics. Currently, the potential new targets for CVD therapeutics appear to be less obvious, and many CVD diseases may be less amenable to target-based research, because CVD 
